288 related articles for article (PubMed ID: 10925532)
1. In vitro activity of quinupristin/dalfopristin against gram-positive bacteria Haemophilus influenzae and Branhamella catarrhalis in Taiwan.
Wang FD; Lin ML; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jun; 63(6):433-9. PubMed ID: 10925532
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of quinupristin/dalfopristin and other antibiotics against ampicillin-resistant enterococcus faecium.
Wang FD; Liu IM; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):119-23. PubMed ID: 10677922
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of macrolides against gram-positive aerobes, Haemophilus influenzae, Moraxella catarrhalis and Bacteroides fragilis in Taiwan.
Wang FD; Liu IM; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Apr; 62(4):230-5. PubMed ID: 10367484
[TBL] [Abstract][Full Text] [Related]
5. In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698.
Lofland D; Difuntorum S; Waller A; Clements JM; Weaver MK; Karlowsky JA; Johnson K
J Antimicrob Chemother; 2004 Apr; 53(4):664-8. PubMed ID: 14973152
[TBL] [Abstract][Full Text] [Related]
6. Comparative activity of quinupristin/dalfopristin and RPR 106972 and the effect of medium on in-vitro test results.
King A; May J; Phillips I
J Antimicrob Chemother; 1998 Dec; 42(6):711-9. PubMed ID: 10052893
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of quinupristin/dalfopristin against clinical isolates of common gram-positive bacteria in Taiwan.
Chang SC; Fang CT; Hsueh PR; Luh KT; Hsieh WC
Diagn Microbiol Infect Dis; 1999 Apr; 33(4):299-303. PubMed ID: 10212757
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
Jones RN; Ballow CH; Biedenbach DJ; Deinhart JA; Schentag JJ
Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.
Tünger A; Aydemir S; Uluer S; Cilli F
Indian J Med Res; 2004 Dec; 120(6):546-52. PubMed ID: 15654141
[TBL] [Abstract][Full Text] [Related]
10. In vitro antimicrobial activity and MIC quality control guidelines of RPR 106972 (RPR 112808/RPR106950): a novel orally administered streptogramin combination. The Quality Control Study Group.
Putnam SD; Jones RN; Johnson DM
Diagn Microbiol Infect Dis; 1997 Jul; 28(3):139-47. PubMed ID: 9294704
[TBL] [Abstract][Full Text] [Related]
11. Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes.
Baudoux P; Lemaire S; Denis O; Tulkens PM; Van Bambeke F; Glupczynski Y
J Antimicrob Chemother; 2010 Jun; 65(6):1228-36. PubMed ID: 20378672
[TBL] [Abstract][Full Text] [Related]
12. Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.
Finch RG
Drugs; 1996; 51 Suppl 1():31-7. PubMed ID: 8724814
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
Jacobs E; Dalhoff A; Korfmann G
Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
[TBL] [Abstract][Full Text] [Related]
14. Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in two university hospitals in Istanbul, Turkey.
Gonullu N; Catal F; Kucukbasmaci O; Ozdemir S; Torun MM; Berkiten R
Chemotherapy; 2009; 55(3):161-7. PubMed ID: 19390189
[TBL] [Abstract][Full Text] [Related]
15. [Comparative antimicrobial activity of RP 59,500 (quinupristin-dalfopristin), the first semisynthetic injectable streptgramin, against gram-positive cocci and other recent clinical pathogens].
Nakashio S; Iwasawa H; Iino S; Shimada J
Jpn J Antibiot; 1997 Oct; 50(10):844-53. PubMed ID: 9412874
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study.
Sader HS; Jones RN; Ballow CH; Biedenbach DJ; Cered RF;
Braz J Infect Dis; 2001 Feb; 5(1):21-31. PubMed ID: 11290311
[TBL] [Abstract][Full Text] [Related]
17. Quinupristin/Dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium.
Winston DJ; Emmanouilides C; Kroeber A; Hindler J; Bruckner DA; Territo MC; Busuttil RW
Clin Infect Dis; 2000 May; 30(5):790-7. PubMed ID: 10817685
[TBL] [Abstract][Full Text] [Related]
18. PROTEKT 1999-2000: a multicentre study of the antimicrobial susceptibility of respiratory tract pathogens in Japan.
Inoue M; Kohno S; Kaku M; Yamaguchi K; Igari J; Yamanaka K
Int J Infect Dis; 2005 Jan; 9(1):27-36. PubMed ID: 15603993
[TBL] [Abstract][Full Text] [Related]
19. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
Jacobs MR; Felmingham D; Appelbaum PC; Grüneberg RN;
J Antimicrob Chemother; 2003 Aug; 52(2):229-46. PubMed ID: 12865398
[TBL] [Abstract][Full Text] [Related]
20. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.
Lamb HM; Figgitt DP; Faulds D
Drugs; 1999 Dec; 58(6):1061-97. PubMed ID: 10651391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
